Ferumoxytol is a parenteral iron replacement indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier. MedsAcross supplies Ferumoxytol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
FERABRIGHT is indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier. FERABRIGHT is an iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.
Source: US FDA prescribing information
Ferumoxytol is a superparamagnetic iron oxide coated with a carbohydrate shell that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues on T1-weighted MRI. Disruption of the blood-brain barrier allows distribution of ferumoxytol into lesions such as neoplasms. Since extravasation of the large ferumoxytol molecules is slow, parenchymal enhancement is seen in the delayed phase, approximately 24 hours post-administration of FERABRIGHT.
Source: US FDA prescribing information
The recommended dose of FERABRIGHT is based on patient weight: 50 kg or less: 300 mg of elemental iron administered as a single intravenous infusion over at least 15 minutes. 51 kg or more: 510 mg of elemental iron administered as a single intravenous infusion over at least 15 minutes. FERABRIGHT must be diluted before administration in either 0.9% sodium chloride injection or 5% dextrose injection to achieve concentrations of 2 mg/mL to 8 mg/mL of elemental iron. Obtain post-contrast T1-weighted images approximately 24 hours after administration.
Source: US FDA prescribing information
FERABRIGHT is contraindicated in patients with known hypersensitivity to ferumoxytol, any of FERABRIGHT’s components, or any other intravenous iron products. Reactions have included anaphylaxis. Known hypersensitivity to ferumoxytol, any of FERABRIGHT’s components, or any other intravenous iron products
Source: US FDA prescribing information
Boxed warning (anaphylaxis and other serious hypersensitivity reactions): Fatal and serious hypersensitivity reactions, including anaphylaxis, have occurred in patients receiving ferumoxytol products that contain the same active ingredient as FERABRIGHT. Initial signs may include hypotension, syncope, unresponsiveness, and cardiac/cardiorespiratory arrest. Hypotension: Monitor for signs and symptoms of hypotension following administration. Iron Overload: Avoid use of FERABRIGHT in patients with iron overload. Magnetic Resonance Imaging Test Interference: Conduct anticipated MRI studies (other than the intended FERABRIGHT brain imaging) prior to the administration of FERABRIGHT or use T1- or proton density-weighted pulse sequences if MRI is required within 3 months after administration.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Anaphylaxis and Other Serious Hypersensitivity Reactions Hypotension The most common adverse reactions (≥0.65%) are nausea, pruritus, constipation, headache, diarrhea, increased blood pressure, bleeding, hyperpigmentation, vein injury, taste alteration, burning/tingling sensation with injection, red sclera, allergic rhinitis, back pain, vomiting, and increased ALT.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Ferumoxytol, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| FeraBright 300 mg/10 mL injectionIntravenous | Azurity Pharmaceuticals | US FDA | Available on request |
| FeraBright 510 mg/17 mL injectionIntravenous | Azurity Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 2 presentations of Ferumoxytol and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Ferumoxytol, including FeraBright.
Yes. The US FDA first approved Ferumoxytol on 30 June 2009, according to Drugs@FDA.
No listed presentation of Ferumoxytol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Ferumoxytol is classified under ATC code B03AC (Sodium ferric gluconate complex).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.